Results 31 to 40 of about 3,063 (143)

Pharmacokinetics of baricitinib in critically ill COVID-19 patients

, 2023
International audienceBackground: The use of the selective Janus Kinase 1/2 inhibitor baricitinib has shown a survival benefit in mechanically ventilated COVID-19 patients but this is not without adverse drug reactions.
Pierre Fillatre, Nicolas Massart, Florian Lemaitre, Camille Tron, Massart, Nicolas, Fillatre, Pierre, Lemaitre, Florian, Tron, Camille, Arnaud Mari, Mari, Arnaud   +9 more
core   +1 more source

Analysis of Tofacitinib and Baricitinib as Second and third Line treatment in theumatoid arthritis: systematic review of cost effectiveness studies

, 2021
Introducción: La Artritis Reumatoide una enfermedad crónica, con daño irreversible, es importante conocer los costos asociados a su tratamiento, el cual tiene como objeto llevar al paciente a un estado de remisión.
Betancur Romero, John Edison, Carrasco Muñoz, Paola Andrea   +1 more
core   +1 more source

Real-World Analysis of Therapeutic Patterns in Patients Affected by Rheumatoid Arthritis in Italy: A Focus on Baricitinib

Rheumatology and Therapy, 2020
Introduction The objective of this study was to evaluate treatment patterns in patients with rheumatoid arthritis (RA), with a focus on the utilization of baricitinib, an oral highly selective Janus kinase 1 and 2 inhibitor, in an Italian real-world ...
Valentina Perrone, Serena Losi, Veronica Rogai, Silvia Antonelli, Walid Fakhouri, Massimo Giovannitti, Elisa Giacomini, Diego Sangiorgi, Luca Degli Esposti   +8 more
doaj   +1 more source

Two Phase 3 Trials of Baricitinib for Alopecia Areata

, 2022
BACKGROUND & nbsp;Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an oral, selective, reversible inhibitor of Janus kinases 1 and 2, may
Hordinsky, Maria, Holzwarth, Katrin, Wu, Wen-Shuo, Ohyama, Manabu, Zlotogorski, Abraham, Kwon, Ohsang, Chiasserini, Chiara, King, Brett, Ko, Justin, Yu, Guanglei, DeLozier, Amy M., Stanley, Sarah, Dutronc, Yves, McCollam, Jill, Mesinkovska, Natasha A., Sinclair, Rodney   +15 more
core   +1 more source

Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro

Dose-Response, 2022
Objective To evaluate the clinical efficacy and safety of baricitinib, a Janus kinase (JAK) inhibitor, in treating patient with progressing vitiligo, and to further explore the regulation of baricitinib on melanocytes (MCs) in vitro.
Jie Dong, Xuan Huang, Li-Ping Ma, Fei Qi, Si-Nian Wang, Zi-Qin Zhang, Shi-Nan Wei, Ling Gao, Fang Liu   +8 more
doaj   +1 more source

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis [PDF]

, 2019
OBJECTIVE: To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately-to-severely active ...
Takeuchi, Tsutomu, Gonzalez-Gay, MA, Burmester, Gerd R., Cardoso, Anabela, Takeuchi, T, Issa, Maher, Witt, Sarah, Saifan, Chadi, Taylor, Peter, Walls, Chad D., Rooney, Terence P., Chad D. Walls, Anabela Cardoso, Gerd R. Burmester, Miguel A. González‐Gay, Terence P. Rooney, Peter C. Taylor, Saifan, C, Cardoso, A, Zhang, Xin, Weinblatt, ME, Sarah Witt, Issa, M, Xin Zhang, Burmester, GR, Zhang, X, Witt, S, Taylor, PC, Claudia A. Salinas, Maher Issa, Chadi Saifan, Walls, CD, Salinas, CA, Tsutomu Takeuchi, Taylor, Peter C., Weinblatt, Michael E., Rooney, TP, Michael E. Weinblatt, González-Gay Mantecón, Miguel Ángel, Salinas, Claudia A.   +39 more
core   +1 more source

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison

RMD Open, 2020
Objective To compare improvement in pain and physical function for patients treated with baricitinib, adalimumab, tocilizumab and tofacitinib monotherapy from randomised, methotrexate (MTX)-controlled trials in conventional synthetic disease-modifying ...
P Emery, M Van de Laar, R Fleischmann, B Fautrel, P C Taylor, I De La Torre, B Zhu, F De Leonardis, C L Kannowski, C Nicolay, Z Kadziola   +10 more
doaj   +1 more source

Baricitinib versus placebo or adalimumab in rheumatoid arthritis [PDF]

, 2017
Background Baricitinib is an oral, reversible, JAK1/JAK2 inhibitor that may have therapeutic value in patients with rheumatoid arthritis. Methods In this 52-week, phase 3, double-blind, placebo and active-controlled study, 1307 patients with active ...
Jaime Reyes Gonzaga, Gaich, C, Tanaka, Y, Sergey Yakushin, Ishii, Taeko, Taylor, P, Emoto, K, Taylor, P.C., Scott Beattie, Stephanie de Bono, Arora, V., van der Heijde, D, de Bono, Stephanie, Carol Gaich, Yakushin, S., Peter C. Taylor, Taeko Ishii, Weinblatt, ME, Beattie, S., Rooney, T., Yakushin, S, Terence Rooney, Reyes Gonzaga, J, Ishii, T, Keystone, Edward C., Morales, L.D., Heijde, D. van der, Weinblatt, Michael E., Macias, William L., Tanaka, Y., Michael E. Weinblatt, Vipin Arora, Schlichting, Douglas, Schlichting, D, Gaich, Carol, Reyes Gonzaga, Jaime, Liliana del Carmen Morales, Bono, S. de, William L. Macias, Taylor, Peter, Tanaka, Yoshiya, de Bono, S, Douglas Schlichting, Arora, Vipin, Emoto, K., Weinblatt, M.E., Macias, W.L., Yakushin, Sergey, Beattie, S, Arora, V, Désirée van der Heijde, Emoto, Kahaku, Macias, WL, Rooney, Terence, Yoshiya Tanaka, Edward C. Keystone, Schlichting, D., Gaich, C., Rooney, T, Keystone, E.C., Kahaku Emoto, del Carmen Morales, Liliana, Keystone, EC, Ishii, T., Gonzaga, J.R., Van der Heijde, Désirée, Beattie, Scott, del Carment Morales, L   +67 more
core   +1 more source

Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date

, 2023
Alopecia areata (AA) is a chronic, tissue-specific autoimmune disorder, characterized by non-scaring hair loss, with a global prevalence of approximately 2%. Typically, it affects a young population, with initial onset frequently occurring before the age
Tiago Torres, Sofia Faria, Egídio Freitas   +2 more
core   +1 more source

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial [PDF]

, 2018
© 2018 Elsevier Ltd Background: Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with ...
Cardiel, M. H., Kalunian, K. C., Furie, R. A., Dörner, T., Hoffman, R. W., +7 additional authors, Petri, M. A., Wallace, D. J., Tanaka, Y., Bruce, I. N., Mosca, M.   +10 more
core   +2 more sources